We are live on ! Find out more
NVET

Nexvet Biopharma plc Ordinary Shares
NVET

Delisted

NVET was delisted on the 28th of July, 2017.

Back to rankings

0 hedge funds and large institutions have $0 invested in Nexvet Biopharma plc Ordinary Shares in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 20 → 0 (-20)

100% less capital invested

Capital invested by funds: $35.8M → $0 (-$35.8M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 20

Holders
–
Holders Change
-20
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$17.7M
2
BC
Broadfin Capital
New York
-$7.54M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$5.32M
4
KAM
Kassirer Asset Management
Ontario, Canada
-$803K
5
HCMT
Highland Capital Management (Texas)
Texas
-$702K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
– -$17.7M -2,648,696 Closed
BC
2
Broadfin Capital
New York
– -$7.54M -1,127,200 Closed
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
– -$5.32M -795,000 Closed
KAM
4
Kassirer Asset Management
Ontario, Canada
– -$803K -120,000 Closed
HCMT
5
Highland Capital Management (Texas)
Texas
– -$702K -105,000 Closed
GF
6
Gabelli Funds
New York
– -$588K -87,900 Closed
PAMP
7
Polar Asset Management Partners
Ontario, Canada
– -$569K -85,000 Closed
GCIA
8
Gabelli & Co Investment Advisers
New York
– -$476K -71,100 Closed
GP
9
GLG Partners
United Kingdom
– -$402K -60,098 Closed
SMC
10
S. Muoio & Co
New York
– -$387K -57,790 Closed
HM
11
Harvest Management
New York
– -$335K -50,000 Closed
GCL
12
Glazer Capital LLC
New York
– -$284K -42,605 Closed
Norges Bank
13
Norges Bank
Norway
– -$229K -34,313 Closed
DAM
14
DLD Asset Management
New York
– -$174K -26,000 Closed
PCM
15
Prelude Capital Management
New York
– -$153K -22,876 Closed
Deutsche Bank
16
Deutsche Bank
Germany
– -$23K -3,500 Closed
Morgan Stanley
17
Morgan Stanley
New York
– -$21K -3,178 Closed
UBS Group
18
UBS Group
Switzerland
– -$16K -2,445 Closed
FPF
19
FNY Partners Fund
New York
– -$15K -2,300 Closed
Bank of America
20
Bank of America
North Carolina
– -$5K -800 Closed

NVET Hedge Fund Activity: Q3 2017 in Review

0 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q3 2017, worth a combined $0 — down 100% from $35.8M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of NVET and 0 opened new positions — a net loss of 20 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Farallon Capital Management, exiting entirely with an estimated $17.7M sold.

  • 0 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q3 2017, down from 20 in Q2 2017.
  • Funds reported $0 of Nexvet Biopharma plc Ordinary Shares stock for Q3 2017, down 100% quarter-over-quarter.
  • 0 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q3 2017 and 20 closed out, a net change of -20 holders.
  • The largest Nexvet Biopharma plc Ordinary Shares seller in Q3 2017 was Farallon Capital Management, an estimated $17.7M sold.

Based on aggregated 13F filings for Q3 2017.